Why a UK petition for mandatory ADHD education should become a national conversation about schools, healthcare, employment and government responsibility
Dr. Emmanuel Eni Amadi, PhD, MBA
ADHD Assessment and Diagnostic Clinician | Adult, Children and Young People with ADHD | Pharmacist Independent Prescriber | Former Superintendent Pharmacist Director & CEO | Medical Scientist | Pharmaceutical Executive
Adult ADHD Clinical Evidence Series | Special Policy and Public Health Commentary | 5 November 2026.
The Child Behind the Headlines
I decided to draft this article tonight, 05 November 2026, when I returned home from the Glasgow Royal Infirmary, Glasgow, Scotland, after a brief medical examination. My wife was in the driver's seat while I was busy in the passenger seat, browsing news updates on my mobile phone and reading an interesting article on ADHD Diagnosis published on 30 October 2026 by the BBC, titled: “ADHD education petition reaches 10,000 signatures”.
What happens when a child struggles to concentrate, interrupts lessons, cannot sit still or repeatedly fails to complete schoolwork?
Do we ask what the child needs?
Or do we simply decide that the child is difficult?
On 30 October 2026, BBC journalist Emily Johnson reported that a parliamentary petition launched by Ryan Swain, from Malton in North Yorkshire, had attracted 10,000 signatures within two weeks [1].
Swain, who described growing up with undiagnosed ADHD and Tourette's syndrome, was permanently excluded from mainstream education at the age of 14. As a father of two young teenagers, I would not have taken that exclusion lightly.
His campaign calls for age-appropriate education about ADHD and neurodivergence in schools.
As a father of two sons, this debate resonates with me personally. I vividly remember returning home from work in Manchester when my sons, then aged approximately ten and eight, sat me down at our dining table. They had questions about sexual intercourse and how they were conceived, following what they had been taught at primary school. My older son even used his fingers to demonstrate what he understood from the lesson.
I was taken aback. I called my wife and asked, “Honey, what are you teaching these boys? She then told me that the children said they were taught sex at school. I felt deeply uncomfortable, disheartened and concerned that such explicit information had been introduced at an age when, in my view, my children were not sufficiently mature to process sexual intercourse. I believe parents should have meaningful involvement in decisions about the timing, content and delivery of sensitive educational subjects.
This remains my personal conviction as a father, and I stand by it.
That experience also raises a wider question about our educational priorities. If schools can introduce sensitive subjects to children at an early age, why should they not also introduce carefully designed, age-appropriate education about ADHD, autism and other neurodevelopmental differences?
I am not suggesting that children should diagnose themselves or their classmates. Rather, I believe they should be taught empathy, respect and an understanding that individuals think, learn, communicate and regulate their emotions differently.
For me, the question is not simply what children are taught, but When, How, and Why they are taught it.
The petition raises an important public policy question: Should understanding neurodevelopmental differences be an essential part of education rather than something children discover only after difficulties emerge?
The petition's popularity demonstrates public engagement, although it does not establish how effective mandatory classroom teaching would be. That question requires evidence, thoughtful policy design and evaluation.
My perspective is informed by more than 26 years of professional experience in pharmacy, healthcare and clinical leadership, including approximately a decade of involvement in mental-health-related clinical services.
Since approximately 2015, alongside my responsibilities as a pharmacy owner and Superintendent Pharmacist Director, I have undertaken locum clinical assignments in England, including work across NHS hospital and general practice settings. My responsibilities have included patient-facing medicines optimisation, mental-health medication reviews, clinical consultations and multidisciplinary collaboration.
Within general practice, I conducted medication reviews through face-to-face appointments, telephone consultations and, where available, video consultations. This work involved reviewing psychiatric medication regimens, considering treatment effectiveness and tolerability, assessing patient-reported symptoms, identifying potential medication-related problems and contributing to clinical decision-making within the relevant professional governance arrangements.
My clinical exposure also included participation in mental-health assessment and diagnostic processes, with appropriate medical or psychiatric oversight. This experience strengthened my understanding of structured clinical assessment, differential diagnosis, patient safety, documentation and the importance of multidisciplinary care.
At that stage, I was practising within my pharmacist's professional remit and did not hold independent prescribing authority. My role should therefore be distinguished from autonomous psychiatric diagnosis or independent prescribing.
More recently, I completed specialist Adult ADHD training through the UK Adult ADHD Network (UKAAN), followed by supervised clinical development involving ADHD assessment, structured diagnostic interviews, clinical formulation, medication reviews, treatment initiation and titration processes, and ongoing monitoring.
In September 2026, I qualified as a Pharmacist Independent Prescriber, with my annotation subsequently approved by the General Pharmaceutical Council.
This combination of longstanding mental-health medicines management experience, specialist ADHD training, supervised clinical practice and independent prescribing qualification informs my approach to evidence-based neurodevelopmental healthcare.
I do not claim to have spent ten years independently diagnosing ADHD. Rather, I bring substantial experience in mental-health-related pharmaceutical care, supported by more recent specialist training and supervised ADHD clinical development.
As a result, I believe the discussion on neurodevelopmental conditions including ADHD should extend beyond awareness.
It should address recognition, educational support, diagnostic quality, clinical treatment, workplace inclusion and the transition into adult life.
1. ADHD Is Not Simply Bad Behaviour
Attention-deficit hyperactivity disorder (ADHD) is a neurodevelopmental condition characterised by persistent patterns of inattention and/or hyperactivity–impulsivity that interfere with functioning or development.
Its presentation varies considerably.
One child may be visibly restless and impulsive. Another may appear quiet but struggle to organise tasks, retain instructions or sustain attention.
Some children experience substantial difficulties despite strong intellectual ability.
The World Federation of ADHD International Consensus Statement, developed by researchers across 27 countries, identified 208 evidence-supported conclusions about the condition [2].
The evidence demonstrates that ADHD is a well-established clinical condition, not simply a fashionable label or an excuse for poor behaviour.
The statement reported pooled prevalence estimates of approximately 5.9% among young people and 2.5% among adults, although estimates vary according to methodology and diagnostic criteria [2].
These figures should encourage governments to consider ADHD as a significant population-level educational and healthcare issue.
But recognition must not become indiscriminate labelling.
Not every restless, inattentive or disruptive child has ADHD.
Learning difficulties, trauma, anxiety, sleep problems, sensory needs and other developmental or medical conditions can produce overlapping presentations.
Understanding ADHD means recognising these complexities rather than replacing one stereotype with another.
2. The Cost of Being Misunderstood
Educational difficulties associated with ADHD can extend well beyond individual classroom incidents.
Arnold and colleagues conducted a systematic review of long-term academic outcomes, identifying 176 studies examining educational achievement and performance [3].
The review found that academic outcomes were frequently poorer among individuals with untreated ADHD than among comparison groups.
These findings do not mean that every child with ADHD will struggle academically, nor do they prove that all adverse outcomes are directly caused by ADHD.
Nevertheless, they demonstrate why early recognition and effective support matter.
Repeated disciplinary action may address an immediate behavioural incident without addressing the underlying difficulties contributing to it.
For some children, the consequences may accumulate: disengagement, reduced confidence, poorer attendance and strained relationships with teachers or peers.
Permanent exclusion is a serious educational outcome. However, it would be inappropriate to assume that ADHD alone explains any individual exclusion.
The better question is whether schools consistently identify and respond to neurodevelopmental needs before difficulties escalate.
A child should not have to experience educational failure before adults begin asking whether additional support is needed.
3. Awareness Is Not Diagnosis
Ryan Swain's petition makes a persuasive case for improving understanding.
But there is an essential distinction between educating children about ADHD and diagnosing ADHD.
The UK's National Institute for Health and Care Excellence (NICE) guideline NG87 specifies that ADHD diagnosis should be undertaken by an appropriately qualified specialist with relevant training and expertise [4].
Diagnosis requires comprehensive clinical assessment, including developmental and psychiatric history, information about symptoms across settings, functional impairment and consideration of coexisting conditions.
NICE also explicitly advises against universal ADHD screening in nursery, primary and secondary schools.
These positions are compatible.
Schools should understand ADHD. Teachers should recognise possible difficulties. Qualified healthcare professionals should establish diagnoses.
Age-appropriate education could help pupils understand differences in attention, organisation, emotional regulation and learning.
It could also encourage empathy and reduce inappropriate assumptions about classmates.
However, classroom teaching must avoid encouraging children to diagnose themselves or their peers.
Awareness should create a pathway towards understanding and appropriate support, not a culture of casual diagnostic labels.
4. Teachers Need Training, Not Just Awareness Posters
An awareness campaign may attract attention.
Sustainable change requires practical knowledge.
NICE NG87 already recommends local initiatives that provide teachers with information about ADHD characteristics and basic behavioural management [4].
The challenge is translating such recommendations into consistent educational practice.
Teachers need to understand that ADHD-related difficulties can vary by context, age, task demands and the presence of coexisting conditions.
Practical approaches may include:
Clear, concise instructions supported by written reminders.
Breaking complex tasks into manageable stages.
Reducing unnecessary distractions.
Providing predictable routines and appropriate movement breaks.
Using constructive feedback and proportionate behaviour-management strategies.
Collaborating with families and special educational needs professionals.
These measures should be individualised rather than imposed uniformly.
Importantly, reasonable educational support should not always depend on waiting for a formal diagnosis. NICE recognises that some support can begin while difficulties are being evaluated [4].
Mandatory ADHD education, if introduced, should therefore form one part of a wider programme involving staff development, family engagement, specialist referral pathways and evaluation.
5. The Transition Problem: Children Become Adults
One of the greatest weaknesses in fragmented healthcare systems is the transition from childhood services into adult care.
A young person may receive educational support, medication monitoring and specialist clinical input during adolescence, only to encounter difficulties when responsibilities shift between services.
NICE NG87 recommends reassessment at school-leaving age where appropriate and coordinated transition planning when continuing treatment is needed [4].
This matters because ADHD does not necessarily disappear when someone turns 18.
Symptoms may change with age, but difficulties involving organisation, time management, emotional regulation and sustained attention may continue.
For some adults, these challenges become more apparent when the structured support of school or family is replaced by university, employment, financial responsibilities and independent living.
A policy focused exclusively on childhood awareness would therefore be incomplete.
Education, healthcare and employment systems should be connected across the lifespan.
6. Employers: ADHD Does Not End at the School Gate
The same individual who struggled with deadlines at school may later struggle with competing priorities, interruptions and administrative demands at work.
Yet workplace ADHD is frequently discussed through simplistic assumptions.
An employee who misses deadlines may be labelled careless.
Someone who requires written instructions may be regarded as insufficiently attentive.
An otherwise capable professional who struggles with repetitive administrative tasks may be perceived as inconsistent.
These difficulties should not automatically be attributed to ADHD. However, when ADHD is present, they may represent genuine functional challenges.
NICE specifically identifies employment, environmental modifications and workplace adjustments as important topics following diagnosis [4].
Employers can consider practical changes such as clearer task prioritisation, written instructions, structured feedback, reduced unnecessary interruptions and flexibility where operationally reasonable.
In the UK, the Equality Act 2010 may require employers to make reasonable adjustments where ADHD meets the legal definition of disability.
Not every person with ADHD will require the same adjustments, and a diagnosis does not remove legitimate performance expectations.
The objective is to enable people to meet appropriate expectations without avoidable disadvantage.
Workplace inclusion should be measured by whether people can contribute effectively, not merely by whether an organisation has published a neurodiversity statement.
7. Treatment Matters — But Medication Is Not the Entire Answer
ADHD awareness should lead to informed decisions about support and treatment, not assumptions that every diagnosed person needs medication.
A major international systematic review and network meta-analysis led by Cortese and colleagues examined 133 double-blind randomised controlled trials involving children, adolescents and adults [5].
The analysis found that several ADHD medications improved core symptoms compared with placebo over the short term, although efficacy and tolerability differed between medications and age groups.
The authors also highlighted limitations in longer-term randomised evidence.
This supports an important principle: effective treatment is available, but clinical decisions must be individualised.
NICE recommends considering environmental modifications, educational and occupational needs, psychological support and medication where indicated [4].
Medication initiation requires appropriate specialist expertise and baseline assessment, followed by careful titration and monitoring.
For children, parents and teachers can contribute important information about functional outcomes.
For adults, treatment goals may include improvements in organisation, daily responsibilities, relationships and occupational functioning.
The ultimate goal is not simply reducing a symptom score.
It is improving meaningful functioning and quality of life.
8. An International Evidence Base - A Shared Responsibility
ADHD research is international.
The World Federation's consensus statement brings together contributions from leading researchers across North America, Europe, Asia and other regions [2].
Its findings demonstrate why ADHD should be considered through a global scientific framework rather than through isolated national controversies.
Research institutions and clinical networks in the United Kingdom, United States, Canada, Germany and elsewhere have contributed to advances in understanding ADHD's development, assessment, associated impairment and treatment.
However, the existence of an international research consensus does not automatically establish which educational policy will work best in a particular country.
For example, the evidence supporting ADHD as a clinical condition is much stronger than direct evidence establishing the effectiveness of one specific mandatory school-awareness curriculum.
Governments should distinguish these questions.
The scientific evidence justifies taking ADHD seriously.
The educational intervention itself should be carefully designed, piloted and evaluated.
9. What Should Government Do Next?
The campaign reported by the BBC creates an opportunity for a constructive national response.
I would recommend five priorities.
First: Introduce age-appropriate neurodevelopmental education.
Pupils should learn that people differ in attention, learning and self-regulation, without being encouraged to label or diagnose one another.
Second: Strengthen teacher training.
Teachers and school leaders need practical, evidence-informed guidance on identifying difficulties, adapting learning environments and accessing appropriate support.
Third: Improve early support and specialist pathways.
Schools, families, primary care and specialist services should communicate effectively. Children with significant difficulties should not be left unsupported while awaiting assessment.
Fourth: Protect continuity into adulthood.
Education and healthcare systems should coordinate transition planning, including support for further education, employment and ongoing treatment where necessary.
Fifth: Measure outcomes.
Government should evaluate whether interventions improve understanding, pupil wellbeing, educational participation, appropriate referral, staff confidence and equitable access to support.
Awareness campaigns should be judged by their effects, not simply by the number of posters distributed or events held.
10. My Clinical and Professional Perspective
My professional perspective has developed through more than 26 years in pharmacy and healthcare, including approximately a decade of mental-health-related clinical experience in England.
Since approximately 2015, I have undertaken locum assignments involving NHS hospital and general practice settings, alongside my previous responsibilities as a pharmacy owner and Superintendent Pharmacist Director.
Within primary care, my responsibilities included psychiatric medication reviews, medicines optimisation and patient consultations conducted face-to-face, by telephone and, where available, through video appointments. I also gained experience participating in mental-health assessment and diagnostic processes under appropriate medical or psychiatric oversight.
These experiences strengthened my understanding of mental-health presentations, medication safety, multidisciplinary working and the importance of structured clinical reasoning.
My subsequent specialist Adult ADHD training through UKAAN, together with supervised clinical development involving ADHD assessment, diagnostic formulation, medication reviews, treatment initiation and titration, provided a more focused foundation in neurodevelopmental healthcare.
I qualified as a Pharmacist Independent Prescriber in September 2026.
I distinguish my longstanding experience in mental-health-related pharmaceutical care from my more recent specialist ADHD diagnostic training. Both have contributed to my conviction that effective ADHD care requires more than awareness: it requires competent assessment, sound clinical judgement, appropriate treatment, educational support and effective clinical governance.
My PhD research in Medical Sciences has also reinforced the importance of critically evaluating evidence before drawing conclusions.
For these reasons, I believe our response to ADHD should be guided by scientific evidence, clinical competence, compassion and a commitment to improving meaningful outcomes.
11. The Question We Should All Be Asking
Ryan Swain's campaign has generated attention because it speaks to an experience that many families recognise: the possibility of a child being misunderstood before their needs are properly explored.
We cannot retrospectively determine how any individual life would have unfolded under different circumstances.
But we can improve the systems that future children encounter.
We can train teachers.
We can strengthen clinical pathways.
We can support families.
We can help employers understand neurodevelopmental differences.
And we can ensure that educational policy is informed by credible science rather than stigma.
The objective is not to excuse every behaviour. It is to understand the person, identify the difficulty and respond appropriately.
A school should be a place where children are educated, supported and challenged to develop their abilities.
A workplace should be a place where people can contribute according to their capabilities.
And a healthcare system should offer competent assessment and evidence-based care.
Before we exclude another child, perhaps our first question should be: Have we done enough to understand and support them?
That is a question for educators, clinicians, employers, policymakers and society.
References
[1] Johnson, E. (2026) 'ADHD education petition reaches 10,000 signatures', BBC News, 30 October. Available at: https://www.bbc.co.uk/news/articles/c3qjn8nq4dxdo (Accessed: 5 November 2026).
[2] Faraone, S.V. et al. (2021) 'The World Federation of ADHD International Consensus Statement: 208 evidence-based conclusions about the disorder', Neuroscience & Biobehavioral Reviews, 128, pp. 789–818. https://doi.org/10.1016/j.neubiorev.2021.01.022
Full text: https://pmc.ncbi.nlm.nih.gov/articles/PMC8328933/
[3] Arnold, L.E., Hodgkins, P., Kahle, J., Madhoo, M. and Kewley, G. (2020) 'Long-term outcomes of ADHD: Academic achievement and performance', Journal of Attention Disorders, 24(1), pp. 73–85. https://doi.org/10.1177/1087054714566076
[4] National Institute for Health and Care Excellence (NICE) (2018, updated 2019) Attention deficit hyperactivity disorder: Diagnosis and management. NICE guideline NG87. Available at: https://www.nice.org.uk/guidance/ng87/chapter/recommendations (Accessed: 5 November 2026).
[5] Cortese, S. et al. (2018) 'Comparative efficacy and tolerability of medications for attention-deficit hyperactivity disorder in children, adolescents, and adults: A systematic review and network meta-analysis', The Lancet Psychiatry, 5(9), pp. 727–738. https://doi.org/10.1016/S2215-0366(18)30269-4
Author biography:
Dr Emmanuel Eni Amadi, PhD, MBA, is a medical scientist, GPhC-registered Pharmacist Independent Prescriber, UKAAN-trained Adult ADHD Clinician and healthcare leader. His professional background encompasses 26 years in pharmacy and healthcare, approximately a decade of broader mental-health-related experience, and supervised specialist ADHD clinical development. His interests include neurodevelopmental healthcare, evidence-based prescribing, clinical governance, healthcare leadership and public education.
Professional disclaimer:
This article is an independent educational and policy commentary. It does not represent the views of the BBC, NICE, NHS or any government body. It is not intended as individual medical advice.
